In a study published in journal Nature Immunology, researchers led by UNC Lineberger member Jenny P.Y. Ting, PhD, describe how inflammation can go unchecked in the absence of a certain inflammation inhibitor called NLRP12. In a harmful feedback loop, this inflammation can upset the balance of bacteria living in the gut. Beneficial bacterial may be the key to reversing inflammation in the absence of this key regulator.
H. Shelton Earp, MD, director of UNC Cancer Care and the Lineberger Professor of Cancer Research, and Jenny P.Y. Ting, PhD, UNC Lineberger member and William Rand Kenan Professor of Genetics, have been honored with the Hyman L. Battle Distinguished Cancer Research Award.
The early-stage cellular immunotherapy trials are for patients with either Hodgkin lymphoma or non-Hodgkin lymphoma, who lack other treatment options or are at high risk of their disease returning.
Using dye to map cancer metastases, Emma Rossi, MD, and UNC collaborators lead large study to help patients avoid complications from surgery.
With a $1.74 million grant from the NIH, UNC Lineberger researchers led by H. Shelton Earp, MD, will study a potential new strategy for improving immunotherapy drug responses in patients with melanoma.
UNC scientists led by John Sondek, PhD, created a new biochemical tool to block specific types of downstream G-protein signaling, opening new avenues of research and potential drug design and discovery.
Less than 50 percent of surveyed teens found it ‘very believable’ that cigars are not a safe alternative to cigarettes, according to a first-of-its-kind UNC School of Medicine study.
UNC Lineberger researchers led by Dr. Timothy R. Gershon report preclinical findings showing promise for targeting a gene linked to microcephaly in infants as a treatment for medulloblastoma.
In the journal Cancer Epidemiology, Biomarkers & Prevention, researchers report that uninsured women under age 65 who received their mammogram at community screening clinics in North Carolina were less likely to get follow-up within a year of a positive mammogram, and had higher odds of missing a 60-day window for follow-up care.
Susan G. Komen announced UNC Lineberger researcher Charles M. Perou, PhD, as the recipient of this year's Brinker Award for Scientific Distinction in Basic Science for his contributions to the understanding of breast cancer as distinct molecular subtypes that have prognostic value using cutting-edge cancer genomics tools.
In the study published in the Journal of Clinical Oncology, UNC Lineberger researchers report that nearly a third of a group of patients with chronic myeloid leukemia, and who have federally-funded Medicare health insurance, did not start treatment within six months of diagnosis with any of three targeted drugs that have led to dramatic improvements in survival for the disease.
